Dilution is now out of the way and shares of ARTH have almost doubled in the last three months.
The company is nearing clinical trials with a product likely to fly through the regulatory hurdles. Looking ahead, ARTH looks like a great investment in the biotechnology space.
It has a market cap of under $25 million in a space where companies at the same stage of development are going public with billion dollar market caps. Lastly, competition does not exist, meaning AC5 will be highly successful
With aging populations in the States and Europe, the number of surgeries are expected to grow radically. Larger companies are gobbling up novel tissue sealants. It looks like ARTH is on the right track for a major breakout.
Also, I think most people assume that ARTH will seek regulatory approval in Europe before the U.S. If so, AC5 might be in the market within the next two-three years, something investors aren't currently anticipating.